Protective effects of long term antiplatelet and anticoagulant therapy in hospitalized patients with inflammatory bowel disease  

作　　者：Madhav Changela Sagar Pandey Janak Bahirwani Nishit Patel Maulik Kaneriya Sanket D Basida Anish Shah Rahul Thakur Krishna Bodrya Suruchi Jai Kumar Ahuja Yecheskel Schneider 

机构地区：[1]Department of Internal Medicine,One Brooklyn Health System/Interfaith Medical Center,Brooklyn,NY 11213,United States [2]Department of Gastroenterology,St.Luke's University Health Network,Bethlehem,PA 18015,United States [3]Department of Internal Medicine,University of Missouri,Columbia,MO 65212,United States [4]Department of Internal Medicine,Bronxcare Health System,Bronx,NY 10457,United States [5]Department of Internal Medicine,Albert Einstein College of Medicine/Jacobi Medical Center,Bronx,NY 10461,United States [6]Department of Internal Medicine,Lehigh Valley Health Network,Easton,PA 18045,United States [7]Department of Data Sciences,Sarepta Therapeutics,Cambridge,MA 02124,United States

出　　处：《World Journal of Gastrointestinal Pharmacology and Therapeutics》2024年第6期28-38,共11页世界胃肠药理与治疗学杂志（英文）

摘　　要：BACKGROUND Inflammatory bowel disease(IBD),with its rising prevalence rates is associated with an increased risk of cardiovascular and thromboembolic events.Antiplatelets and/or anticoagulants agents are often prescribed but the literature on the impact of long-term anticoagulation and/or antiplatelet use among patients hospitalized with IBD is scarce.The aim of this study is to assess the outcomes of patients hospitalized with IBD on antiplatelet and/or anticoagulant agents.AIM To investigate the effects of long-term use of antiplatelets/anticoagulants on clinical outcomes in patients hospitalized with IBD.METHODS We conducted a retrospective cohort study using the Nationwide Inpatient Sample database,including all adult IBD patients hospitalized in the United States from 2016 to 2019.Patient cohorts were stratified based on antiplatelet/anticoagulant therapy status.Multivariate regression analysis was done to assess outcomes,adjusting for potential confounders.The primary outcome was mortality,whereas length of stay(LOS),total parenteral nutrition,acute kidney injury,sepsis,shock,gastrointestinal bleeding,need for colonoscopy/sigmoidoscopy,abdominal surgery and total hospitalization charges were secondary outcomes.RESULTS Among 374744 hospitalized IBD patients,antiplatelet or anticoagulant therapy alone was associated with significantly lower in-hospital mortality and reduced healthcare utilization,including shorter LOS and decreased hospitalization costs.Combined therapy was associated with a protective effect on mortality,but did not reach statistical significance.Notably,therapy did not exacerbate disease severity or complications,although higher odds of gastrointestinal bleeding were observed.CONCLUSION Our study highlights the potential benefits of long-term anticoagulation/antiplatelet therapy in hospitalized IBD patients,with improved mortality outcomes and healthcare utilization.While concerns regarding gastrointestinal bleeding exist,the overall safety profile suggests a role for these agents in mitiga

关 键 词：Inflammatory bowel disease ANTICOAGULATION Antiplatelet therapy Healthcare utilization MORTALITY 

分 类 号：R574[医药卫生—消化系统]